Skip to main content
OpenTrials
Completed

NCT Number: NCT02503059

Etanercept Survival in Elderly Population

Evaluate the 3-year survival of etanercept in patients over 60 years with psoriasis in moderate / severe plaque and the reasons that led to the abandonment. Besides factors that might have had a positive or negative influence on adherence to treatment and analysis of efficacy (PASI 75) and safety will be identified.

All variables were collected through retrospective review of medical records of patients dermatology unit are made.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

60 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Clinic, Barcelona, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with moderate / severe psoriasis (with / without psoriatic arthritis,PAs) defined by: PASI(Psoriasis Area and Severity Index)> 10 and / or BSA(Body Surface Area)> 10% and / or DLQI(Dermatology Life Quality Index)> 10
  • PASI> 10 and / or BSA(Body Surface Area)> 10% and / or DLQI(Dermatology Life Quality Index)> 10
  • Over 60 years of age at the start of treatment
  • Receiving etanercept at any time
  • Available history in the Dermatology

Exclusion criteria

  • Patients with insufficient clinical data in the medical record

Treatment and study plan

Primary outcomes

  1. primary ineffectiveness in patients with etanercept treatment

    Time frame: 24 weeks

    Number of participants not achieve PASI 50 response at 12 weeks

  2. Secondary ineffectiveness in patients with etanercept treatment

    Time frame: 24 weeks (duration of treatment with etanercept)

    Number of participants with Poor adherence to treatment with etanercept",

  3. Ineffectiveness of treatment in localized lesions in patients with etanercept treatment

    Time frame: 24 weeks(duration of treatment with etanercept)

    Despite having achieved a good response PASI no improvement in critical injuries

  4. primary ineffectiveness in patients with etanercept treatment

    Time frame: 24 weeks

    Number of participants not achieve PASI 75 response at 24 weeks

Secondary outcomes

  1. Number of participants with adverse events during treatment with etanercept

    Time frame: 24 weeks

  2. Number of participants with disease remission

    Time frame: 24 weeks

  3. number of participants with Poor adherence to treatment with etanercept

    Time frame: 24 weeks

  4. number of participants with Conditions requiring hospitalization and / or surgery

    Time frame: 24 weeks

Sponsors and collaborators

Lead sponsor

Fundación Pública Andaluza Progreso y Salud

Other

Registry information

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Jul 20, 2015
Registry last updated
Jul 20, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.